$300 Million

Gilead Sciences, Inc.

Buy-side

Financial Advisor, July 2020

Exclusive Option to Acquire Tizona Therapeutics

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Tizona is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people with cancer. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Its novel pipeline includes the clinical-stage TTX-080, an anti-HLA-G antibody, and rich preclinical portfolio. Tizona investors include MPM, Canaan, Abingworth, Interwest Partners, Lightstone Ventures, Amgen Ventures, Astellas Venture Management, and AbbVie Ventures.

More Like This

Jun 2020

Merger with MYOS RENS Technology, Inc.

Financial Advisor

View Details
Jun 2020
$1.4 Billion

Acquisition of ArcherDX, Inc.

Financial Advisor

View Details
Dec 2019

Acquisition of Ondal Holding GmbH

Financial Advisor

View Details